Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.42 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.42 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.42 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.42 |
| ▸ | STIM2 | Q9P246 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14972983 | 0.85 | MAPT (0.49) | NPC1LMNAMAPTSMN1; SMN2RAB9A | |
| SCHEMBL5382860 | 0.85 | SMN1; SMN2 (0.58) | NPC1LMNASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL14973224 | 0.84 | MAPT (0.48) | NPC1LMNAMAPTSMN1; SMN2RAB9A | |
| SCHEMBL3354812 | 0.84 | NPC1 (0.56) | NPC1LMNAMAPTSMN1; SMN2KMT2A | |
| SCHEMBL14973210 | 0.80 | MAPT (0.50) | NPC1LMNAMAPTSMN1; SMN2RAB9A | |
| SCHEMBL14973236 | 0.78 | MAPT (0.43) | NPC1LMNAMAPTSMN1; SMN2RAB9A | |
| SCHEMBL16246946 | 0.77 | NPC1 (0.58) | NPC1LMNAMAPTSMN1; SMN2RAB9A | |
| SCHEMBL2508219 | 0.76 | NPC1 (0.55) | NPC1LMNAMAPTSMN1; SMN2RAB9A | |
| SCHEMBL2819339 | 0.76 | GRM2 (0.42) | NPC1LMNAMAPTSMN1; SMN2RAB9A | |
| SCHEMBL21333190 | 0.75 | SMN1; SMN2 (0.60) | NPC1LMNASMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | NPC1 366/4885LMNA 1512/4885MAPT 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.